Background

Biologic selection in SLE remains empirical. Belimumab (anti-BAFF) and rituximab (anti-CD20) target distinct B-cell survival and depletion mechanisms, yet no validated biomarker guides the choice between them. B-cell receptor (BCR) somatic hypermutation (SHM) load reflects germinal center activity and affinity maturation intensity — processes differentially dependent on BAFF signaling versus CD20-expressing cell pools.

Hypothesis

Circulating plasmablast BCR heavy-chain SHM load, quantified by targeted next-generation sequencing of VDJ regions at baseline, stratifies SLE patients into BAFF-dependent (high SHM, active germinal centers) versus extrafollicular (low SHM, short-lived plasmablasts) pathogenic B-cell programs. High SHM load (>8 mutations/VH region) predicts superior response to belimumab (BAFF blockade disrupts germinal center output), while low SHM load (<4 mutations/VH) predicts superior response to rituximab (direct depletion of extrafollicular short-lived effectors).

Testable Predictions

1. Baseline plasmablast SHM load >8 mutations/VH predicts SRI-4 response to belimumab at week 12 with AUC >0.80
2. Baseline SHM load <4 mutations/VH predicts complete B-cell depletion and SLEDAI improvement ≥4 points with rituximab at week 12 with AUC >0.78
3. Intermediate SHM (4–8 mutations/VH) identifies mixed pathogenesis where combination or sequential therapy outperforms monobiologic
4. SHM load correlates with serum BAFF levels (r >0.5) and inversely with anti-dsDNA avidity index

Proposed Methodology

• Prospective observational cohort, n≥120 SLE patients initiating belimumab or rituximab
• Baseline: FACS-sorted CD19dimCD27++CD38++ plasmablasts → targeted VDJ amplicon sequencing (IgH)
• SHM quantification: mutation count per VH gene segment, normalized by germline
• Primary endpoint: SRI-4 at week 12; secondary: SLEDAI change, complement normalization, anti-dsDNA titer reduction
• Statistical analysis: Bayesian logistic regression with SHM load × treatment interaction, adjusted for baseline SLEDAI, ethnicity, prior immunosuppression
• Validation: 10-fold cross-validation + external cohort replication

Limitations

• Plasmablast sorting requires fresh samples and specialized flow cytometry
• VDJ sequencing cost (~$200/sample) may limit scalability
• Rituximab arm may have selection bias (often used after belimumab failure)
• SHM load may vary with disease duration and prior treatments
• Single-timepoint measurement may miss dynamic SHM evolution

Clinical Significance

A BCR SHM-based companion diagnostic would transform SLE biologic selection from trial-and-error to mechanism-guided therapy. Correct first-line biologic selection could reduce the 6–12 month delay currently caused by empirical switching, decrease cumulative organ damage, and lower healthcare costs. The assay is technically feasible with existing clinical NGS infrastructure.

LES AI • DeSci Rheumatology